Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
861 to 880 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Case Report: Next-Generation Sequencing Reveals Tumor Origin in a Female Patient With Brain Metastases. | Front Oncol | 2021 | 33912440 | PubTator, text mining | PubMed |
| A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. | Transl Lung Cancer Res | 2021 | 33889528 | PubTator, text mining | PubMed |
| Wobble tRNA modification and hydrophilic amino acid patterns dictate protein fate. | Nat Commun | 2021 | 33859181 | PubTator, text mining | PubMed |
| Synthetic lethality-mediated precision oncology via the tumor transcriptome. | Cell | 2021 | 33857424 | PubTator, text mining | PubMed |
| Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC). | Hum Genomics | 2021 | 33845897 | PubTator, text mining | PubMed |
| C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. | Sci Adv | 2021 | 33837088 | PubTator, text mining | PubMed |
| A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report. | Ann Palliat Med | 2021 | 33832282 | PubTator, text mining | PubMed |
| Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement. | Virchows Arch | 2021 | 33825946 | PubTator, text mining | PubMed |
| A new KIF5B-ERBB4 gene fusion in a lung adenocarcinoma patient. | ERJ Open Res | 2021 | 33816604 | PubTator, text mining | PubMed |
| Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer. | Front Oncol | 2021 | 33816312 | PubTator, text mining | PubMed |
| Genetic Neuropathy Due to Impairments in Mitochondrial Dynamics. | Biology (Basel) | 2021 | 33810506 | PubTator, text mining | PubMed |
| The Fusion Gene Landscape in Taiwanese Patients with Non-Small Cell Lung Cancer. | Cancers (Basel) | 2021 | 33809651 | PubTator, text mining | PubMed |
| Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2021 | 33807876 | PubTator, text mining | PubMed |
| Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. | Cancers (Basel) | 2021 | 33806977 | PubTator, text mining | PubMed |
| Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. | Cancers (Basel) | 2021 | 33806299 | PubTator, text mining | PubMed |
| Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. | Int J Mol Sci | 2021 | 33803747 | PubTator, text mining | PubMed |
| Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs. | J Clin Med | 2021 | 33801014 | PubTator, text mining | PubMed |
| Cytoskeletal Transport, Reorganization, and Fusion Regulation in Mast Cell-Stimulus Secretion Coupling. | Front Cell Dev Biol | 2021 | 33796537 | PubTator, text mining | PubMed |
| Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. | Mol Pharmacol | 2021 | 33795352 | PubTator, text mining | PubMed |
| Micro1278 Leads to Tumor Growth Arrest, Enhanced Sensitivity to Oxaliplatin and Vitamin D and Inhibits Metastasis via KIF5B, CYP24A1, and BTG2, Respectively. | Front Oncol | 2021 | 33791222 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=44